HRP20201171T1 - Derivati izoindolin-1-ona kao modulatori aktivnosti pozitivnog alosternog modulatora kolinergijskog muskarinskog m1 receptora za liječenje alzheimerove bolesti - Google Patents
Derivati izoindolin-1-ona kao modulatori aktivnosti pozitivnog alosternog modulatora kolinergijskog muskarinskog m1 receptora za liječenje alzheimerove bolesti Download PDFInfo
- Publication number
- HRP20201171T1 HRP20201171T1 HRP20201171TT HRP20201171T HRP20201171T1 HR P20201171 T1 HRP20201171 T1 HR P20201171T1 HR P20201171T T HRP20201171T T HR P20201171TT HR P20201171 T HRP20201171 T HR P20201171T HR P20201171 T1 HRP20201171 T1 HR P20201171T1
- Authority
- HR
- Croatia
- Prior art keywords
- group
- groups
- optionally substituted
- halogen atom
- pharmaceutically acceptable
- Prior art date
Links
- 208000024827 Alzheimer disease Diseases 0.000 title claims 4
- 238000011282 treatment Methods 0.000 title claims 4
- 102000007207 Muscarinic M1 Receptor Human genes 0.000 title 1
- 108010008406 Muscarinic M1 Receptor Proteins 0.000 title 1
- 230000001713 cholinergic effect Effects 0.000 title 1
- 230000000694 effects Effects 0.000 title 1
- PXZQEOJJUGGUIB-UHFFFAOYSA-N isoindolin-1-one Chemical class C1=CC=C2C(=O)NCC2=C1 PXZQEOJJUGGUIB-UHFFFAOYSA-N 0.000 title 1
- 125000005843 halogen group Chemical group 0.000 claims 32
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 31
- 150000001875 compounds Chemical class 0.000 claims 18
- 150000003839 salts Chemical class 0.000 claims 18
- 125000006615 aromatic heterocyclic group Chemical group 0.000 claims 17
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 17
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims 16
- 125000002950 monocyclic group Chemical group 0.000 claims 16
- 125000001424 substituent group Chemical group 0.000 claims 13
- 125000004093 cyano group Chemical group *C#N 0.000 claims 12
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 8
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 6
- 125000006704 (C5-C6) cycloalkyl group Chemical group 0.000 claims 5
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 4
- 125000005115 alkyl carbamoyl group Chemical group 0.000 claims 4
- 125000003118 aryl group Chemical group 0.000 claims 4
- 206010012289 Dementia Diseases 0.000 claims 3
- 206010067889 Dementia with Lewy bodies Diseases 0.000 claims 3
- 201000002832 Lewy body dementia Diseases 0.000 claims 3
- 208000002193 Pain Diseases 0.000 claims 3
- 208000018737 Parkinson disease Diseases 0.000 claims 3
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims 3
- 238000011321 prophylaxis Methods 0.000 claims 3
- 201000000980 schizophrenia Diseases 0.000 claims 3
- 208000019116 sleep disease Diseases 0.000 claims 3
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- WFSARWQASFQZMG-VXKWHMMOSA-N 4-fluoro-2-[(3S,4S)-4-hydroxyoxan-3-yl]-5-methyl-6-[(4-pyrazol-1-ylphenyl)methyl]-3H-isoindol-1-one Chemical compound FC1=C2CN(C(C2=CC(=C1C)CC1=CC=C(C=C1)N1N=CC=C1)=O)[C@H]1COCC[C@@H]1O WFSARWQASFQZMG-VXKWHMMOSA-N 0.000 claims 1
- PQTDWVGBNKIBKC-VXKWHMMOSA-N O[C@@H]1[C@H](CCCC1)N1C(C2=CC(=C(C(=C2C1)C)C)CC=1C=NC(=CC1)C)=O Chemical group O[C@@H]1[C@H](CCCC1)N1C(C2=CC(=C(C(=C2C1)C)C)CC=1C=NC(=CC1)C)=O PQTDWVGBNKIBKC-VXKWHMMOSA-N 0.000 claims 1
- TYTRQXGARQKALD-VXKWHMMOSA-N O[C@@H]1[C@H](COCC1)N1C(C2=CC(=C(C(=C2C1)C)C)CC1=CC=C(C=C1)OC)=O Chemical compound O[C@@H]1[C@H](COCC1)N1C(C2=CC(=C(C(=C2C1)C)C)CC1=CC=C(C=C1)OC)=O TYTRQXGARQKALD-VXKWHMMOSA-N 0.000 claims 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 1
- 125000003226 pyrazolyl group Chemical group 0.000 claims 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/4035—Isoindoles, e.g. phthalimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/44—Iso-indoles; Hydrogenated iso-indoles
- C07D209/46—Iso-indoles; Hydrogenated iso-indoles with an oxygen atom in position 1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Rheumatology (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Anesthesiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Claims (19)
1. Spoj, naznačen time, što je predstavljen formulom (I):
[image]
u kojoj
R1 je
(1) fenilna skupina, skupina C5-6 cikloalkil, 5- ili 6-člana monociklička ne-aromatska heterociklička skupina ili 5- ili 6-člana monociklička aromatska heterociklička skupina, od kojih je svaka proizvoljno supstituirana s 1 do 3 supstituenta koji su odabrani od
(i) halogenog atoma,
(ii) cijano skupine,
(iii) hidroksi skupine,
(iv) skupine C1-6 alkil proizvoljno supstituirane s 1 do 3 hidroksi skupine, i
(v) skupine C1-6 alkoksi, ili
(2) skupina C1-6 alkil proizvoljno supstituirana s 1 do 3 supstituenta koji su odabrani od
(i) hidroksi skupine, i
(ii) 3- do 14-člane ne-aromatske heterocikličke skupine;
R2 je
(1) vodikov atom,
(2) halogeni atom, ili
(3) skupina C1-6 alkil;
R3 je
(1) vodikov atom,
(2) halogeni atom,
(3) cijano skupina,
(4) skupina C1-6 alkil proizvoljno supstituirana s 1 do 3 halogena atoma,
(5) skupina C1-6 alkoksi, ili
(6) skupina C3-6 cikloalkil;
R4 je
(1) halogeni atom,
(2) cijano skupina,
(3) skupina C1-6 alkil,
(4) skupina C1-6 alkoksi proizvoljno supstituirana s 1 do 3 halogena atoma,
(5) karbamoil skupina,
(6) mono- ili di-C1-6 alkil-karbamoil skupina, ili
(7) 5- ili 6-člana monociklička aromatska heterociklička skupina proizvoljno supstituirana s 1 do 3 skupine C1-6 alkil; i
Prsten A je 6-člani aromatski prsten koji je proizvoljno dodatno supstituiran s 1 do 3 supstituenta, dodatno uz R4, odabrana od
(a) halogenog atoma,
(b) skupine C1-6 alkil, i
(c) skupine C1-6 alkoksi,
ili njegova farmaceutski prihvatljiva sol.
2. Spoj prema patentnom zahtjevu 1, naznačen time, što djelomična struktura predstavljena sa sljedećom formulom:
[image]
u formuli (I) je djelomična struktura predstavljena sa sljedećom formulom:
[image]
,
ili njegova farmaceutski prihvatljiva sol.
3. Spoj prema patentnom zahtjevu 1, naznačen time, što
R1 je
(1) fenilna skupina proizvoljno supstituirana s 1 do 3 supstituenta koji su odabrani od
(i) halogenog atoma, i
(ii) cijano skupine,
(2) skupina C5-6 cikloalkil proizvoljno supstituirana s 1 do 3 supstituenta koji su odabrani od
(i) hidroksi skupine,
(ii) skupine C1-6 alkil proizvoljno supstituirane s 1 do 3 hidroksi skupine, i
(iii) skupine C1-6 alkoksi,
(3) 5- ili 6-člana monociklička ne-aromatska heterociklička skupina proizvoljno supstituirana s 1 do 3 hidroksi skupine,
(4) 5- ili 6-člana monociklička aromatska heterociklička skupina proizvoljno supstituirana s 1 do 3 halogena atoma, ili
(5) skupina C1-6 alkil proizvoljno supstituirana s 1 do 3 supstituenta koji su odabrani od
(i) hidroksi skupine, i
(ii) 3- do 8-člane monocikličke ne-aromatske heterocikličke skupine;
R2 je
(1) vodikov atom,
(2) halogeni atom, ili
(3) skupina C1-6 alkil;
R3 je
(1) vodikov atom,
(2) halogeni atom,
(3) cijano skupina,
(4) skupina C1-6 alkil proizvoljno supstituirana s 1 do 3 halogena atoma,
(5) skupina C1-6 alkoksi, ili
(6) skupina C3-6 cikloalkil;
R4 je
(1) halogeni atom,
(2) cijano skupina,
(3) skupina C1-6 alkil,
(4) skupina C1-6 alkoksi proizvoljno supstituirana s 1 do 3 halogena atoma,
(5) karbamoil skupina,
(6) mono- ili di-C1-6 alkil-karbamoil skupina, ili
(7) 5- ili 6-člana monociklička aromatska heterociklička skupina proizvoljno supstituirana s 1 do 3 skupine C1-6 alkil; i
Prsten A je 6-člani aromatski prsten koji je proizvoljno dodatno supstituiran s 1 do 3 supstituenta, dodatno uz R4, odabrana od
(a) halogenog atoma,
(b) skupine C1-6 alkil, i
(c) skupine C1-6 alkoksi,
ili njegova farmaceutski prihvatljiva sol.
4. Spoj prema patentnom zahtjevu 3, naznačen time, što djelomična struktura predstavljena sa sljedećom formulom:
[image]
u formuli (I) je djelomična struktura predstavljena sa sljedećom formulom:
[image]
,
ili njegova farmaceutski prihvatljiva sol.
5. Spoj prema patentnom zahtjevu 1, naznačen time, što
R1 je
(1) fenilna skupina proizvoljno supstituirana s 1 do 3 supstituenta koji su odabrani od
(i) halogenog atoma, i
(ii) cijano skupine,
(2) skupina C5-6 cikloalkil proizvoljno supstituirana s 1 do 3 hidroksi skupine,
(3) 5- ili 6-člana monociklička ne-aromatska heterociklička skupina proizvoljno supstituirana s 1 do 3 hidroksi skupine,
(4) 5- ili 6-člana monociklička aromatska heterociklička skupina proizvoljno supstituirana s 1 do 3 halogena atoma, ili
(5) skupina C1-6 alkil proizvoljno supstituirana s 1 do 3 supstituenta koji su odabrani od
(i) hidroksi skupine, i
(ii) 3- do 8-člane monocikličke ne-aromatske heterocikličke skupine;
R2 je
(1) vodikov atom,
(2) halogeni atom, ili
(3) skupina C1-6 alkil;
R3 je
(1) vodikov atom,
(2) halogeni atom,
(3) cijano skupina,
(4) skupina C1-6 alkil proizvoljno supstituirana s 1 do 3 halogena atoma,
(5) skupina C1-6 alkoksi, ili
(6) skupina C3-6 cikloalkil;
R4 je
(1) halogeni atom,
(2) cijano skupina,
(3) skupina C1-6 alkil,
(4) skupina C1-6 alkoksi proizvoljno supstituirana s 1 do 3 halogena atoma,
(5) karbamoil skupina,
(6) mono- ili di-C1-6 alkil-karbamoil skupina, ili
(7) 5- ili 6-člana monociklička aromatska heterociklička skupina proizvoljno supstituirana s 1 do 3 skupine C1-6 alkil; i
Prsten A je 6-člani aromatski prsten koji je proizvoljno dodatno supstituiran s 1 do 3 supstituenta, dodatno uz R4, odabrana od
(a) halogenog atoma,
(b) skupine C1-6 alkil, i
(c) skupine C1-6 alkoksi,
ili njegova farmaceutski prihvatljiva sol.
6. Spoj prema patentnom zahtjevu 5, naznačen time, što djelomična struktura predstavljena sa sljedećom formulom:
[image]
u formuli (I) je djelomična struktura predstavljena sa sljedećom formulom:
[image]
,
ili njegova farmaceutski prihvatljiva sol.
7. Spoj prema patentnom zahtjevu 1, naznačen time, što
R1 je
(1) fenilna skupina proizvoljno supstituirana s 1 do 3 supstituenta koji su odabrani od
(i) halogenog atoma, i
(ii) cijano skupine,
(2) skupina C5-6 cikloalkil proizvoljno supstituirana s 1 do 3 hidroksi skupine,
(3) 5- ili 6-člana monociklička ne-aromatska heterociklička skupina proizvoljno supstituirana s 1 do 3 hidroksi skupine, ili
(4) skupina C1-6 alkil proizvoljno supstituirana s 1 do 3 supstituenta koji su odabrani od
(i) hidroksi skupine, i
(ii) 3- do 8-člane monocikličke ne-aromatske heterocikličke skupine;
R2 je
(1) vodikov atom,
(2) halogeni atom, ili
(3) skupina C1-6 alkil;
R3 je
(1) vodikov atom,
(2) halogeni atom,
(3) cijano skupina,
(4) skupina C1-6 alkil proizvoljno supstituirana s 1 do 3 halogena atoma,
(5) skupina C1-6 alkoksi, ili
(6) skupina C3-6 cikloalkil;
R4 je
(1) halogeni atom,
(2) cijano skupina,
(3) skupina C1-6 alkil,
(4) skupina C1-6 alkoksi proizvoljno supstituirana s 1 do 3 halogena atoma,
(5) mono- ili di-C1-6 alkil-karbamoil skupina, ili
(6) 5- ili 6-člana monociklička aromatska heterociklička skupina proizvoljno supstituirana s 1 do 3 skupine C1-6 alkil; i
Prsten A je 6-člani aromatski prsten koji je proizvoljno dodatno supstituiran s 1 do 3 supstituenta, dodatno uz R4, odabrana od
(a) halogenog atoma, i
(b) skupine C1-6 alkoksi,
ili njegova farmaceutski prihvatljiva sol.
8. Spoj prema patentnom zahtjevu 7, naznačen time, što djelomična struktura predstavljena sa sljedećom formulom:
[image]
u formuli (I) je djelomična struktura predstavljena sa sljedećom formulom:
[image]
,
ili njegova farmaceutski prihvatljiva sol.
9. Spoj prema patentnom zahtjevu 1, naznačen time, što
R1 je
(1) skupina C5-6 cikloalkil proizvoljno supstituirana s 1 do 3 hidroksi skupine, ili
(2) 5- ili 6-člana monociklička ne-aromatska heterociklička skupina proizvoljno supstituirana s 1 do 3 hidroksi skupine;
R2 je
(1) halogeni atom, ili
(2) skupina C1-6 alkil;
R3 je skupina C1-6 alkil;
R4 je
(1) skupina C1-6 alkil,
(2) skupina C1-6 alkoksi, ili
(3) 5- ili 6-člana monociklička aromatska heterociklička skupina; i
Prsten A je benzenov prsten ili piridinski prsten, od kojih je svaki nesupstituiran, dodatno uz R4,
ili njegova farmaceutski prihvatljiva sol.
10. Spoj prema patentnom zahtjevu 9, naznačen time, što djelomična struktura predstavljena sa sljedećom formulom:
[image]
u formuli (I) je djelomična struktura predstavljena sa sljedećom formulom:
[image]
,
ili njegova farmaceutski prihvatljiva sol.
11. Spoj prema patentnom zahtjevu 1, naznačen time, što
R1 je
(1) skupina cikloheksil supstituirana s jednom hidroksi skupinom, ili
(2) skupina tetrahidropiranil supstituirana s jednom hidroksi skupinom;
R2 je
(1) halogeni atom, ili
(2) skupina C1-6 alkil;
R3 je skupina C1-6 alkil;
R4 je
(1) skupina C1-6 alkil,
(2) skupina C1-6 alkoksi, ili
(3) skupina pirazolil; i
Prsten A je benzenov prsten ili piridinski prsten, od kojih je svaki nesupstituiran, dodatno uz R4,
ili njegova farmaceutski prihvatljiva sol.
12. Spoj prema patentnom zahtjevu 11, naznačen time, što djelomična struktura predstavljena sa sljedećom formulom:
[image]
u formuli (I) je djelomična struktura predstavljena sa sljedećom formulom:
[image]
,
ili njegova farmaceutski prihvatljiva sol.
13. Spoj prema patentnom zahtjevu 1, naznačen time, što je 2-[(3S,4S)-4-hidroksitetrahidro-2H-piran-3-il]-6-(4-metoksibenzil)-4,5-dimetil-2,3-dihidro-1H-izoindol-1-on, ili njegova farmaceutski prihvatljiva sol.
14. Spoj prema patentnom zahtjevu 1, naznačen time, što je 4-fluoro-2-[(3S,4S)-4-hidroksitetrahidro-2H-piran-3-il]-5-metil-6-[4-(1H-pirazol-1-il)benzil]-2,3-dihidro-1H-izoindol-1-on, ili njegova farmaceutski prihvatljiva sol.
15. Spoj prema patentnom zahtjevu 1, naznačen time, što je 2-((1S,2S)-2-hidroksicikloheksil)-4,5-dimetil-6-((6-metilpiridin-3-il)metil)izoindolin-1-on, ili njegova farmaceutski prihvatljiva sol.
16. Lijek, naznačen time, što sadrži spoj prema patentnom zahtjevu 1 ili njegovu farmaceutski prihvatljivu sol.
17. Lijek prema patentnom zahtjevu 16, naznačen time, što je sredstvo za profilaksu ili liječenje Alzheimerove bolesti, shizofrenije, boli, poremećaja spavanja, demencije kod Parkinsonove bolesti ili demencije s Lewyjevim tjelešcima.
18. Spoj prema patentnom zahtjevu 1 ili njegova farmaceutski prihvatljiva sol, naznačen time, što se koristi za profilaksu ili liječenje Alzheimerove bolesti, shizofrenije, boli, poremećaja spavanja, demencije kod Parkinsonove bolesti ili demencije s Lewyjevim tjelešcima.
19. Uporaba spoja prema patentnom zahtjevu 1 ili njegove farmaceutski prihvatljive soli, naznačena time, što je za proizvodnju sredstva za profilaksu ili liječenje Alzheimerove bolesti, shizofrenije, boli, poremećaja spavanja, demencije kod Parkinsonove bolesti ili demencije s Lewyjevim tjelešcima.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2014089585 | 2014-04-23 | ||
| EP15726362.5A EP3134386B1 (en) | 2014-04-23 | 2015-04-22 | Isoindoline-1-one derivatives as cholinergic muscarinic m1 receptor positive alloesteric modulator activity for the treatment of alzheimers disease |
| PCT/JP2015/062912 WO2015163485A1 (en) | 2014-04-23 | 2015-04-22 | Isoindoline-1-one derivatives as cholinergic muscarinic m1 receptor positive alloesteric modulator activity for the treatment of alzheimers disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20201171T1 true HRP20201171T1 (hr) | 2020-11-13 |
Family
ID=53276227
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20201171TT HRP20201171T1 (hr) | 2014-04-23 | 2020-07-27 | Derivati izoindolin-1-ona kao modulatori aktivnosti pozitivnog alosternog modulatora kolinergijskog muskarinskog m1 receptora za liječenje alzheimerove bolesti |
Country Status (36)
| Country | Link |
|---|---|
| US (16) | US9868725B2 (hr) |
| EP (1) | EP3134386B1 (hr) |
| JP (1) | JP6517239B2 (hr) |
| KR (1) | KR102349237B1 (hr) |
| CN (1) | CN106536508B (hr) |
| AR (1) | AR100154A1 (hr) |
| AU (1) | AU2015250610B2 (hr) |
| BR (1) | BR112016024472B1 (hr) |
| CA (1) | CA2946519C (hr) |
| CL (1) | CL2016002661A1 (hr) |
| CR (1) | CR20160544A (hr) |
| CY (1) | CY1123569T1 (hr) |
| DK (1) | DK3134386T3 (hr) |
| DO (1) | DOP2016000286A (hr) |
| EA (1) | EA030373B1 (hr) |
| EC (1) | ECSP16090152A (hr) |
| ES (1) | ES2811088T3 (hr) |
| HR (1) | HRP20201171T1 (hr) |
| HU (1) | HUE050543T2 (hr) |
| IL (1) | IL248393B (hr) |
| LT (1) | LT3134386T (hr) |
| MX (1) | MX2016013810A (hr) |
| MY (1) | MY195742A (hr) |
| NZ (1) | NZ725921A (hr) |
| PE (1) | PE20161400A1 (hr) |
| PH (1) | PH12016502095A1 (hr) |
| PL (1) | PL3134386T3 (hr) |
| PT (1) | PT3134386T (hr) |
| RS (1) | RS60524B1 (hr) |
| SG (1) | SG11201608785PA (hr) |
| SI (1) | SI3134386T1 (hr) |
| TN (1) | TN2016000455A1 (hr) |
| TW (1) | TWI664165B (hr) |
| UA (1) | UA122391C2 (hr) |
| UY (1) | UY36091A (hr) |
| WO (1) | WO2015163485A1 (hr) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3581576B1 (en) | 2013-03-15 | 2022-01-26 | Incyte Holdings Corporation | Tricyclic heterocycles as bet protein inhibitors for use in the treatment of a proliferative disease in combination with a janus kinase inhibitor |
| WO2015095492A1 (en) | 2013-12-19 | 2015-06-25 | Incyte Corporation | Tricyclic heterocycles as bet protein inhibitors |
| SG10201809353TA (en) | 2014-04-23 | 2018-11-29 | Incyte Corp | 1H-PYRROLO[2,3-c]PYRIDIN-7(6H)-ONES AND PYRAZOLO[3,4-c]PYRIDIN-7(6H)-ONES AS INHIBITORS OF BET PROTEINS |
| CN106536508B (zh) * | 2014-04-23 | 2019-08-09 | 武田药品工业株式会社 | 用于治疗阿尔茨海默病的具有胆碱能毒蕈碱m1受体正变构调节剂活性的化合物 |
| WO2015174534A1 (ja) | 2014-05-16 | 2015-11-19 | 武田薬品工業株式会社 | 含窒素複素環化合物 |
| JP6571077B2 (ja) | 2014-06-13 | 2019-09-04 | 武田薬品工業株式会社 | 含窒素複素環化合物 |
| JP6599979B2 (ja) | 2014-09-15 | 2019-10-30 | インサイト・コーポレイション | Ｂｅｔタンパク質阻害剤として用いるための三環式複素環化合物 |
| CR20170568A (es) | 2015-06-26 | 2018-04-20 | Takeda Pharmaceuticals Co | Compuesto heterocíclico |
| WO2017069173A1 (ja) | 2015-10-20 | 2017-04-27 | 武田薬品工業株式会社 | 複素環化合物 |
| AR106520A1 (es) | 2015-10-29 | 2018-01-24 | Incyte Corp | Forma sólida amorfa de un inhibidor de proteína bet |
| WO2017107089A1 (en) * | 2015-12-23 | 2017-06-29 | Merck Sharp & Dohme Corp. | 3- (1h-pyrazol-4-yl) pyridineallosteric modulators of the m4 muscarinic acetylcholine receptor |
| US10548877B2 (en) | 2016-03-11 | 2020-02-04 | Takeda Pharmaceutical Company Limited | Aromatic ring compound |
| KR102643344B1 (ko) | 2016-06-20 | 2024-03-07 | 인사이트 코포레이션 | Bet 저해제의 결정질 고체 형태 |
| WO2018005249A1 (en) * | 2016-06-28 | 2018-01-04 | Merck Sharp & Dohme Corp. | Benzoisoquinolinone m1 receptor positive allosteric modulators |
| CN118005619A (zh) * | 2017-02-28 | 2024-05-10 | 武田药品工业株式会社 | 用于生产杂环化合物的方法 |
| EP3612527B1 (en) | 2017-04-18 | 2022-07-20 | Takeda Pharmaceutical Company Limited | Heterocyclic compounds useful as modulators of acetylcholine receptors |
| JP7197472B2 (ja) * | 2017-05-19 | 2022-12-27 | 武田薬品工業株式会社 | スクリーニング方法 |
| WO2018226545A1 (en) | 2017-06-09 | 2018-12-13 | Merck Sharp & Dohme Corp. | Azabicyclo[4.1.0]heptane allosteric modulators of the m4 muscarinic acetylcholine receptor |
| HUE063823T2 (hu) | 2017-06-20 | 2024-02-28 | Heterociklusos vegyület és annak alkalmazása a kolinerg muszkarin M1 receptor pozitív alloszterikus modulátoraként | |
| CN110709401B (zh) | 2017-06-20 | 2023-06-13 | 武田药品工业株式会社 | 杂环化合物 |
| WO2019000237A1 (en) * | 2017-06-27 | 2019-01-03 | Merck Sharp & Dohme Corp. | ALLOSTERIC MODULATORS OF 3- (1H-PYRAZOL-4-YL) PYRIDINE FROM THE M4 ACETYLCHOLINE MUSCARINIC RECEPTOR |
| WO2019000238A1 (en) * | 2017-06-27 | 2019-01-03 | Merck Sharp & Dohme Corp. | 5- (PYRIDIN-3-YL) OXAZOLE ALLOSTERIC MODULATORS OF M4 ACETYLCHOLINE MUSCARINIC RECEPTOR |
| WO2019000236A1 (en) | 2017-06-27 | 2019-01-03 | Merck Sharp & Dohme Corp. | ALLOSTERIC MODULATORS OF 3- (1H-PYRAZOL-4-YL) PYRIDINE FROM THE M4 ACETYLCHOLINE MUSCARINIC RECEPTOR |
| JP2020158392A (ja) * | 2017-07-25 | 2020-10-01 | Ａｇｃ株式会社 | フルオロフェノール誘導体の製造方法及び新規なフルオロ化合物 |
| WO2019102365A1 (en) * | 2017-11-23 | 2019-05-31 | Suven Life Sciences Limited | Substituted azacycles as muscarinic m1 receptor positive allosteric modulators |
| WO2020067456A1 (ja) | 2018-09-28 | 2020-04-02 | 武田薬品工業株式会社 | 複素環化合物 |
| EP3858823A4 (en) | 2018-09-28 | 2022-07-06 | Takeda Pharmaceutical Company Limited | CONDENSED CYCLIC COMPOUND |
| CN112752760B (zh) | 2018-09-28 | 2024-01-19 | 武田药品工业株式会社 | 杂环化合物 |
| CN113329679A (zh) * | 2018-12-28 | 2021-08-31 | 卢遂显 | 检测治疗和预防神经发育障碍的方法 |
| BR112023001585A2 (pt) * | 2020-07-29 | 2023-04-04 | Vivozon Inc | Composto, e, composição farmacêutica para a prevenção ou tratamento de dor |
| EP4447953A1 (en) | 2021-12-13 | 2024-10-23 | Sage Therapeutics, Inc. | Combination of muscarinic receptor positive modulators and nmda positive allosteric modulators |
Family Cites Families (60)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS4416647Y1 (hr) | 1965-05-26 | 1969-07-18 | ||
| JPS60172704A (ja) | 1984-02-14 | 1985-09-06 | Mitsuwa Seiki Co Ltd | 流体アクチユエ−タの制御方法 |
| JP2699511B2 (ja) * | 1988-01-29 | 1998-01-19 | 武田薬品工業株式会社 | 置換アミン類 |
| US5538983A (en) | 1990-05-16 | 1996-07-23 | The Rockefeller University | Method of treating amyloidosis by modulation of calcium |
| TW219935B (hr) | 1991-12-25 | 1994-02-01 | Mitsubishi Chemicals Co Ltd | |
| JPH06220044A (ja) * | 1991-12-25 | 1994-08-09 | Mitsubishi Kasei Corp | ベンズアミド誘導体 |
| GB9409150D0 (en) | 1994-05-09 | 1994-06-29 | Black James Foundation | Cck and gastrin receptor ligands |
| US5744476A (en) | 1994-06-27 | 1998-04-28 | Interneuron Pharmaceuticals, Inc. | Dopamine D1 agonists for the treatment of dementia |
| JP2992677B2 (ja) | 1995-06-05 | 1999-12-20 | 武田薬品工業株式会社 | 骨形成促進医薬組成物 |
| WO1998030243A1 (en) | 1997-01-08 | 1998-07-16 | Warner-Lambert Company | Acetylcholinesterase inhibitors in combination with muscarinic agonists for the treatment of alzheimer's disease |
| US7084126B1 (en) | 2000-05-01 | 2006-08-01 | Healthpartners Research Foundation | Methods and compositions for enhancing cellular function through protection of tissue components |
| WO2002003684A2 (en) | 2000-06-30 | 2002-01-10 | Eli Lilly And Company | Combination for treating psychoses, comprising an antipsychotic and a muscarinic agonist |
| JP2004532200A (ja) | 2001-03-15 | 2004-10-21 | サエジス ファーマシューティカルズ， インコーポレイテッド | 全身性ストレスの後に認識機能を回復するための方法 |
| WO2002081446A1 (en) | 2001-04-06 | 2002-10-17 | Daewoong Co., Ltd. | 3-cyclopentyloxy-4-methoxyphenyl-isoindolinone derivatives and the use thereof |
| WO2002081447A1 (en) | 2001-04-06 | 2002-10-17 | Daewoong Pharmaceutical Co., Ltd. | 3-cyclopentyloxy-4-methoxyphenyl-isothiazolinone derivatives and the use thereof |
| US20040023951A1 (en) | 2001-06-18 | 2004-02-05 | Bymaster Franklin Porter | Combination therapy for treatment of psychoses |
| DE10137163A1 (de) | 2001-07-30 | 2003-02-13 | Bayer Ag | Substituierte Isoindole und ihre Verwendung |
| US20040044023A1 (en) | 2002-08-30 | 2004-03-04 | Marc Cantillon | Compositions and methods for treating or preventing memory impairment |
| US20060233843A1 (en) | 2003-02-19 | 2006-10-19 | Conn P J | Treatment of psychosis with a muscarinic m1 receptor ectopic activator |
| CA2520125A1 (en) | 2003-03-28 | 2004-10-14 | Acadia Pharmaceuticals Inc. | Muscarinic m1 receptor agonists for pain management |
| US20040266659A1 (en) | 2003-06-27 | 2004-12-30 | Stephen LaBerge | Substances that enhance recall and lucidity during dreaming |
| TW200613272A (en) | 2004-08-13 | 2006-05-01 | Astrazeneca Ab | Isoindolone compounds and their use as metabotropic glutamate receptor potentiators |
| WO2006113485A2 (en) | 2005-04-15 | 2006-10-26 | Board Of Trustees Of Michigan State University | Aminergic pharmaceutical compositions and methods |
| US7807706B2 (en) | 2005-08-12 | 2010-10-05 | Astrazeneca Ab | Metabotropic glutamate-receptor-potentiating isoindolones |
| US7868008B2 (en) | 2005-08-12 | 2011-01-11 | Astrazeneca Ab | Substituted isoindolones and their use as metabotropic glutamate receptor potentiators |
| US20110319386A1 (en) | 2005-08-26 | 2011-12-29 | Braincells Inc. | Neurogenesis by muscarinic receptor modulation |
| EP1928437A2 (en) | 2005-08-26 | 2008-06-11 | Braincells, Inc. | Neurogenesis by muscarinic receptor modulation |
| WO2007044937A2 (en) | 2005-10-13 | 2007-04-19 | President And Fellows Of Harvard College | Compositions and methods to modulate memory |
| GB0607949D0 (en) | 2006-04-21 | 2006-05-31 | Minster Res The Ltd | Mono and combination therapy |
| GB0607952D0 (en) | 2006-04-21 | 2006-05-31 | Minster Res Ltd | Novel treatment |
| GB0607946D0 (en) | 2006-04-21 | 2006-05-31 | Minster Res The Ltd | Mono and combination therapy |
| TW200806625A (en) | 2006-05-26 | 2008-02-01 | Astrazeneca Ab | Therapeutic compounds |
| US8143284B2 (en) | 2006-10-05 | 2012-03-27 | Abbott Laboratories | Poly(ADP-ribose)polymerase inhibitors |
| US8618074B2 (en) | 2007-03-15 | 2013-12-31 | Board Of Regents Of The University Of Texas System | GPCR enhanced neuroprotection to treat brain injury |
| AU2008302079A1 (en) | 2007-09-21 | 2009-03-26 | Acadia Pharmaceuticals, Inc. | Co-administration of pimavanserin with other agents |
| WO2009039461A2 (en) | 2007-09-21 | 2009-03-26 | Acadia Pharmaceuticals, Inc. | N-substituted piperidine derivatives as serotonin receptor agents |
| WO2009039635A1 (en) * | 2007-09-24 | 2009-04-02 | Painceptor Pharma Corporation | Methods of modulating neurotrophin-mediated activity |
| US20100267712A1 (en) | 2007-09-27 | 2010-10-21 | The United States of America, as represented by the Secretary, Department of Health and | Isoindoline compounds for the treatment of spinal muscular atrophy and other uses |
| WO2010042603A1 (en) | 2008-10-08 | 2010-04-15 | Cingulate Neuro Therapeutics, Llc | Amyloid and depression |
| WO2010096338A1 (en) | 2009-02-23 | 2010-08-26 | Merck Sharp & Dohme Corp. | PYRAZOLO [4,3-c] CINNOLIN-3-ONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS |
| AU2010221133A1 (en) | 2009-03-05 | 2011-09-22 | Mithridion, Inc. | Compounds and compositions for cognition-enhancement, methods of making, and methods of treating |
| US8877944B2 (en) | 2009-07-14 | 2014-11-04 | Nerviano Medical Sciences S.R.L. | 3-oxo-2,3-dihydro-1H-isoindole-4-carboxamides as PARP inhibitors |
| US20110020423A1 (en) | 2009-07-22 | 2011-01-27 | Puretech Ventures | Methods and compositions for treatment of disorders ameliorated by muscarinic receptor activation |
| US10265311B2 (en) | 2009-07-22 | 2019-04-23 | PureTech Health LLC | Methods and compositions for treatment of disorders ameliorated by muscarinic receptor activation |
| KR101758046B1 (ko) | 2009-12-22 | 2017-07-14 | 버텍스 파마슈티칼스 인코포레이티드 | 포스파티딜이노시톨 3-키나제의 이소인돌리논 억제제 |
| US8314120B2 (en) * | 2010-03-30 | 2012-11-20 | Abbott Gmbh & Co. Kg | Small molecule potentiators of metabotropic glutamate receptors |
| EP2588104B1 (en) * | 2010-07-01 | 2014-12-10 | Merck Sharp & Dohme Corp. | Isoindolone m1 receptor positive allosteric modulators |
| US9549928B2 (en) | 2011-04-29 | 2017-01-24 | The University Of Toledo | Muscarinic agonists as enhancers of cognitive flexibility |
| WO2012158475A1 (en) | 2011-05-17 | 2012-11-22 | Merck Sharp & Dohme Corp. | N-linked lactam m1 receptor positive allosteric modulators |
| WO2012170599A1 (en) | 2011-06-10 | 2012-12-13 | Braincells, Inc. | Neurogenesis by muscarinic receptor modulation |
| EP3153167B1 (en) | 2011-10-28 | 2019-10-02 | Vanderbilt University | Substituted 2-(4-heterocyclylbenzyl)isoindolin-1-one analogs as positive allosteric modulators of the muscarinic acetylcholine receptor m1 |
| WO2013129622A1 (ja) | 2012-03-02 | 2013-09-06 | 武田薬品工業株式会社 | 複素環化合物およびその用途 |
| US20130289019A1 (en) | 2012-04-26 | 2013-10-31 | Amazing Grace, Inc. | Methods of treating behaviorial and/or mental disorders |
| WO2014077401A1 (ja) | 2012-11-19 | 2014-05-22 | 武田薬品工業株式会社 | 含窒素複素環化合物 |
| TW201512197A (zh) | 2013-08-30 | 2015-04-01 | Hoffmann La Roche | 吡咯并吡啶或吡唑并吡啶衍生物 |
| EP3049391B1 (en) | 2013-09-27 | 2018-12-26 | F.Hoffmann-La Roche Ag | Indole and indazole derivatives |
| GB201317363D0 (en) | 2013-10-01 | 2013-11-13 | Eisai Ltd | Novel compounds |
| CN106536508B (zh) * | 2014-04-23 | 2019-08-09 | 武田药品工业株式会社 | 用于治疗阿尔茨海默病的具有胆碱能毒蕈碱m1受体正变构调节剂活性的化合物 |
| CA2996717A1 (en) | 2015-09-11 | 2017-03-16 | Chase Pharmaceuticals Corporation | Muscarinic combination and its use for combating hypocholinergic disorders of the central nervous system |
| WO2018122845A1 (en) | 2016-12-29 | 2018-07-05 | Rvx Therapeutics Ltd. | Methods and compositions for potentiating cns drugs and reducing their side effects |
-
2015
- 2015-04-22 CN CN201580034130.XA patent/CN106536508B/zh active Active
- 2015-04-22 SG SG11201608785PA patent/SG11201608785PA/en unknown
- 2015-04-22 MY MYPI2016703862A patent/MY195742A/en unknown
- 2015-04-22 MX MX2016013810A patent/MX2016013810A/es active IP Right Grant
- 2015-04-22 CR CR20160544A patent/CR20160544A/es unknown
- 2015-04-22 UY UY0001036091A patent/UY36091A/es not_active Application Discontinuation
- 2015-04-22 PL PL15726362T patent/PL3134386T3/pl unknown
- 2015-04-22 US US15/306,012 patent/US9868725B2/en active Active
- 2015-04-22 DK DK15726362.5T patent/DK3134386T3/da active
- 2015-04-22 EA EA201692132A patent/EA030373B1/ru not_active IP Right Cessation
- 2015-04-22 EP EP15726362.5A patent/EP3134386B1/en active Active
- 2015-04-22 RS RS20200816A patent/RS60524B1/sr unknown
- 2015-04-22 LT LTEP15726362.5T patent/LT3134386T/lt unknown
- 2015-04-22 HU HUE15726362A patent/HUE050543T2/hu unknown
- 2015-04-22 BR BR112016024472-9A patent/BR112016024472B1/pt active IP Right Grant
- 2015-04-22 US US14/693,342 patent/US9315458B2/en active Active
- 2015-04-22 KR KR1020167032435A patent/KR102349237B1/ko active IP Right Grant
- 2015-04-22 AU AU2015250610A patent/AU2015250610B2/en active Active
- 2015-04-22 WO PCT/JP2015/062912 patent/WO2015163485A1/en active Application Filing
- 2015-04-22 AR ARP150101206A patent/AR100154A1/es active IP Right Grant
- 2015-04-22 NZ NZ725921A patent/NZ725921A/en unknown
- 2015-04-22 PT PT157263625T patent/PT3134386T/pt unknown
- 2015-04-22 TW TW104112837A patent/TWI664165B/zh active
- 2015-04-22 JP JP2016564111A patent/JP6517239B2/ja active Active
- 2015-04-22 CA CA2946519A patent/CA2946519C/en active Active
- 2015-04-22 PE PE2016002118A patent/PE20161400A1/es unknown
- 2015-04-22 ES ES15726362T patent/ES2811088T3/es active Active
- 2015-04-22 UA UAA201611867A patent/UA122391C2/uk unknown
- 2015-04-22 TN TN2016000455A patent/TN2016000455A1/en unknown
- 2015-04-22 SI SI201531316T patent/SI3134386T1/sl unknown
-
2016
- 2016-02-02 US US15/013,675 patent/US9518042B2/en active Active
- 2016-02-02 US US15/013,625 patent/US9499516B2/en active Active
- 2016-10-12 US US15/291,769 patent/US9675597B2/en active Active
- 2016-10-19 IL IL24839316A patent/IL248393B/en active IP Right Grant
- 2016-10-19 CL CL2016002661A patent/CL2016002661A1/es unknown
- 2016-10-20 PH PH12016502095A patent/PH12016502095A1/en unknown
- 2016-10-20 DO DO2016000286A patent/DOP2016000286A/es unknown
- 2016-11-23 EC ECIEPI201690152A patent/ECSP16090152A/es unknown
- 2016-12-22 US US15/388,834 patent/US9655881B2/en active Active
- 2016-12-22 US US15/388,887 patent/US9662316B2/en active Active
-
2017
- 2017-04-14 US US15/488,002 patent/US9775827B2/en active Active
- 2017-05-30 US US15/608,565 patent/US9789084B2/en active Active
- 2017-05-30 US US15/608,557 patent/US9789083B2/en active Active
- 2017-08-24 US US15/685,800 patent/US20180000780A1/en not_active Abandoned
- 2017-12-04 US US15/830,634 patent/US10457670B2/en active Active
-
2018
- 2018-12-04 US US16/209,349 patent/US10865200B2/en active Active
-
2020
- 2020-07-27 HR HRP20201171TT patent/HRP20201171T1/hr unknown
- 2020-07-27 CY CY20201100688T patent/CY1123569T1/el unknown
- 2020-09-30 US US17/038,917 patent/US20210009572A1/en not_active Abandoned
-
2022
- 2022-07-25 US US17/872,680 patent/US20220411413A1/en not_active Abandoned
-
2023
- 2023-11-08 US US18/504,741 patent/US20240109874A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20201171T1 (hr) | Derivati izoindolin-1-ona kao modulatori aktivnosti pozitivnog alosternog modulatora kolinergijskog muskarinskog m1 receptora za liječenje alzheimerove bolesti | |
| JP2017513894A5 (hr) | ||
| HRP20201216T1 (hr) | PRIPRAVCI I POSTUPCI ZA LIJEČENJE POREMEĆAJA CNS-a | |
| HRP20220414T1 (hr) | Inhibitori lizin specifične demetilaze-1 | |
| HRP20171028T1 (hr) | Indolski i indazolski spojevi koji aktiviraju ampk | |
| CL2015001557A1 (es) | Compuestos derivados e n-(3-{[4-(alquil/cicloalquil-carbonil)piperazin-1-il]metil}fenil)formamida, moduladores del receptor gamma huérfano relacionado con retinoide (ror-gamma); composicion farmaceutica; y su uso en el tratamiento de esclerosis multiple y/o psoriasis. | |
| PE20181144A1 (es) | Derivados de heteroarilo como inhibidores de parp | |
| JP2017502940A5 (hr) | ||
| HRP20170873T1 (hr) | Monociklički derivat piridina | |
| PE20161372A1 (es) | Inhibidores de dihidropirrolopiridina de ror-gamma | |
| FI3406609T3 (fi) | Bisyklisiä atsayhdisteitä muskariinireseptorin agonisteina | |
| MY192521A (en) | Bicyclic-fused heteroaryl or aryl compounds and their use as irak4 inhibitors | |
| PE20141682A1 (es) | Derivados de (4-fenilimidazol-2-il) etilamina utiles como moduladores de canal de sodio | |
| MA35903B1 (fr) | Nouveaux derives d'indolizine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent | |
| JP2018522034A5 (hr) | ||
| HRP20100522T1 (hr) | Piridin karboksamidi kao inhibitori 11-beta-hsd1 | |
| AR078172A1 (es) | Fenoximetil dihidro oxazolopirimidinonas sustituidas y uso de las mismas como moduladores de receptores metabotropicos de mglur | |
| AR104963A1 (es) | Derivados de 2-(pirazolopiridin-3-il)pirimidina como inhibidores de jak | |
| AR092045A1 (es) | Combinaciones farmaceuticas | |
| PE20141167A1 (es) | Piridopirazinas sustituidas como inhibidores novedosos de ptk | |
| JP2018522033A5 (hr) | ||
| HRP20140588T1 (hr) | Spojevi kondenziranog prstena i njihova uporaba | |
| RU2017120217A (ru) | 2-амино-5,5-дифтор-6-(фторметил)-6-фенил-3,4,5,6-тетрагидпропиридины в качестве ингибиторов bace1 | |
| PE20220386A1 (es) | Amidas de pirazolo-piridina sustituidas y su uso como moduladores del receptor glun2b | |
| MX2016008536A (es) | Derivados de fluoro-naftilo. |